厄贝沙坦与氯沙坦治疗轻、中度高血压病的比较

Comparative Efficacy of Irbesartan and Losartan in Mild-to-moderate Hypertension

目的 比较厄贝沙坦与氯沙坦对轻中度高血压病患者的降压疗效。方法 采用随机、双盲研究方法。经 2周的单盲、安慰剂导入期 ,72例坐位舒张压在 95～ 115mmHg之间的高血压患者被随机分入厄贝沙坦 75mg/天组 (n =36 )或氯沙坦 5 0mg/天组 (n =36 )。 4周末 ,如坐位舒张压仍≥ 90mmHg ,每日剂量加倍 (厄贝沙坦 15 0mg/天或氯沙坦 10 0mg/天 ) ,总疗程 8周。结果 两组患者服药后血压均显著降低 (P <0 0 1)。经 8周治疗 ,厄贝沙坦组平均坐位收缩压与舒张压分别降低 15 .0 %与 13.3% ,在氯沙坦组分别为 13.7%与 14.0 %。两药的有效率无显著性差别 (厄贝沙坦 75 .0 % ,氯沙坦 71.4% ,P >0 0 5 )。与厄贝沙坦不同 ,氯沙坦组血尿酸水平显著降低。结论 在轻中度高血压的治疗中 。

Objective To compare the antihypertensive efficacy of irbesartan and losartan in patients with mild to moderate hypertension. Methods A randomized, double blind study was performed. After 2 week, single blind, placebo run in period, 72 patients with a mean seating diastolic blood pressure (SeDBP) of 95 to 115 mmHg were randomly allocated to receive either irbesartan 75 mg once daily ( n =36) or losartan 50 mg once daily ( n =36). At week 4, if SeDBP was ≥90 mmHg, the daily dose was doubled to irbesartan 150 mg or losartan 100 mg. Results Blood pressure was significantly reduced in both groups ( P <0 01). After 8 weeks of therapy, mean seated systolic blood pressure (SeSBP) and SeDBP were reduced by 15.0% and 13.3% respectively in irbesartan, 13.7% and 14.0% in losartan.\ There was no significant difference in the effective rate between irbesartan and losartan (75.0% vs 71.4%, P >0 05). Losartan significantly reduced serum uric acid levels, whereas irbesartan showed little effect on uric acid. Conclusion Irbesartan is effective, safe. Its efficacy is similarto losartan in treating mild to moderate essential hypertension.